๐Ÿ‡ฎ๐Ÿ‡ชIreland
16ยฐC Partly Cloudy ยท Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Yinchuan
Clinical trial register · China

Clinical Trials in Yinchuan, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage โ€” all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 65 Guangzhou 54 Wuhan 33 Shanghai 28 Nanjing 25
Narrow the registerReset
Recruitment status
Phase
Site location
Beijing65 Guangzhou54 Wuhan33 Shanghai28 Nanjing25
All 65 locations
Target enrolment
to

Trials with a site in Yinchuan

5 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Recruiting
A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis
NCT07225504Secondary Progressive Multiple Sclerosis (SPMS)
Novartis Pharmaceuticals
Phase 3
1,275
Guangzhou, Zhengzhou, Wuhan, Hohhot, Suzhou, Changchun, Shenyang, Yinchuan
2025-11-11
Recruiting
Lp(a) Lowering Study of Pelacarsen (TQJ230) With Background Inclisiran in Participants With Elevated Lp(a) and Established ASCVD
NCT06813911Atherosclerotic Cardiovascular Disease (ASCVD)
Novartis Pharmaceuticals
Phase 3
340
Yinchuan, Jining, Xian, Beijing, Shanghai
2025-04-30
Recruiting
Study of Efficacy and Safety of LNP023 in Participants With Active Lupus Nephritis Class III-IV, +/- V
NCT05268289Lupus Nephritis
Novartis Pharmaceuticals
Phase 2
240
Nanning, Wuhan, Shenyang, Yinchuan, Beijing, Shenzhen
2022-08-10
Active, closed
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS) (REMODEL-2)
NCT05156281Relapsing Multiple Sclerosis
Novartis Pharmaceuticals
Phase 3
1,007
Wuhan, Nanjing, Yinchuan, Taiyuan, Hangzhou, Wenzhou, Beijing, Shanghai
2021-12-13
Active, closed
A Rollover Extension Program (REP) to Evaluate the Long-term Safety and Tolerability of Open Label Iptacopan/LNP023 in Participants With Primary IgA Nephropathy
NCT04557462Primary IgA Nephropathy
Novartis Pharmaceuticals
Phase 3
448
Beijing, Guangzhou, Luoyang, Zhengzhou, Changsha, Changchun, Yinchuan, Taiyuan
2021-09-20
Rows per page Showing 1–5 of 5
1
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/yinchuan

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 5 of those studies with a site in Yinchuan that also match the filters currently applied.

How many clinical trials are recruiting in Yinchuan?

3 of the 5 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 0 have not yet opened recruitment, 2 are active but closed to new participants, and 0 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Yinchuan), 5 studies
PhaseStudiesRecruitingShare
Phase 34280%
Phase 21120%

Most active sponsors

Lead sponsors with the most studies (Yinchuan)
Lead sponsorStudiesRecruiting
Novartis Pharmaceuticals53
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.